<headline>Beneath the Drapes
Terry Keating is the new CEO at Eastern Goldfields Division after the departure of Vivian Duggin. Canning Division has lost longstanding CEO Carolyn Lawrence and IT support person John Newman.
Bone Medical has appointed Paul Hopper as chairman. He is based in the US as chairman of Innovative Oncology.
Perth based pSivida Ltd, which is developing nanostructured porous silicon (BioSiliconTM) for health applications, particularly drug delivery, has recently completed Phase II trials of liver cancer treatment, directly targeting radiotherapy into liver tumours (brachytherapy). pSivida's strategic partner is QinetiQ in the UK.
Visiomed Group is now involved in the clinical evaluation of the microEYE ophthalmic imaging system with CustomVis, a company now developing and marketing laser products for refractive eye surgery. CustomVis has Dr Paul van Saarloos as CEO and Dr Mukesh Jain as Marketing Director, both of whom worked to develop the Q-Vis laser refractive system with the Lions Eye Institute before Q-Vis went into receivership despite LEI's major investment.
John Thompson has replaced Dr Paul D'Sylva as non-executive chairman at PharmAust. Paul was the Director of Research and Development at Murdoch Uni before joining PharmAust, and will now head the company's subsidiary Mimotopes, a Melbourne-based discovery chemistry company acquired in March this year. PharmAust successfully raised $5.5 million in October 2004 to develop and expand its drug discovery and drug manufacturing businesses in Australia and SE Asia.
After acquiring Hospital Supplies of Australia (HSA) in 2003, Australian Pharmaceutical Industries (API) has announced HSA is to merge with Clifford Hallam Pharmaceuticals to operate as a separate entity. ABN AMRO Capital are partners in the deal. HSA attracted Ross Davis from Cottman to become its WA manager, before centralizing operations to Sydney. API is focused on pharmacy supplies and has Soul Pattinson, Chemworld, Pharmacist Advice, and Priceline Pharmacy lines within its stable, as well as Halas Dental, Zuellig Pharma, Healthcare Logistics and Price Attack stores.
Sirtex Medical Limited, which has developed biospheres used for targeted liver cancer treatment, has appointed new CEO Mr Gilman Wong and Angela Talbot as CFO. Chairman of the board and product developer is ex-Perth surgeon Dr Bruce Gray, now residing in Sydney.